Showing articles whose micro-themes are very close to:
#Drug reimbursement
- No closely related articles found yet.
- NCPE Recommends Against Reimbursement of Belzutifan (Welireg) for von Hippel-Lindau Disease in Ireland (ncpe.ie) | 15d ago
- Government Commits to Six-Month Deadline for Drug Reimbursement Decisions in Ireland (imt.ie) | 14d ago
- Reimbursement dispute over prostate cancer drug delays patient access (medicalindependent.ie) | 14d ago
- GLP-1 Receptor Agonists Show Potential Cancer Prevention Benefits in Preclinical and Observational Studies (sciencenews.org) | 15d ago
- NCPE Assessment: Belzutifan not cost-effective for VHL disease-associated tumours at current price (ncpe.ie) | 39d ago
- Seanad Éireann Debate on NCPE Cost-Benefit Analysis (oireachtas.ie) | 124d ago
- NCPE Publishes Updated Budget Impact Model Template v2.3 for Drug Reimbursement Submissions (ncpe.ie) | 57d ago
- NCPE Ireland HTA for Opdualag (nivolumab+relatlimab) for advanced melanoma: status update (ncpe.ie) | 18d ago
- NCPE Recommends Belzutifan (Welireg) Not Reimbursed for VHL Disease on Cost-Effectiveness Grounds (ncpe.ie) | 39d ago
Showing page 1 of 1
(9 total results)
← Prev
Next →